If you have been reading about reconstitution and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
=== Measures of success === Success of liquid–liquid extraction is measured through separation factors and decontamination factors. The best way to understand the success of an extraction column is through the liquid–liquid equilibrium (LLE) data set. The data set can then be converted into a curve to determine the steady state partitioning behavior of the solute between the two phases. The y-axis is the concentration of solute in the extract (solvent) phase, and the x-axis is the concentration of the solute in the raffinate phase. From here, one can determine steps for optimization of the process.
== Orthogonal ribosomes == Similarly to orthogonal tRNAs and aminoacyl tRNA synthetases (aaRSs), orthogonal ribosomes have been engineered to work in parallel to the natural ribosomes. Orthogonal ribosomes ideally use different mRNA transcripts than their natural counterparts and ultimately should draw on a separate pool of tRNA as well. This should alleviate some of the loss of fitness which currently still arises from techniques such as Amber codon suppression. Additionally, orthogonal ribosomes can be mutated and optimized for particular tasks, like the recognition of quadruplet codons. Such an optimization is not possible, or highly disadvantageous for natural ribosomes.
is the elastic deformation/deflection. If the contacting bodies are approximated as linear elastic half spaces, the Boussinesq-Cerruti integral equation solution can be applied to express the deformation (
Canada's media is highly autonomous, diverse, and very regionalized. The Broadcasting Act declares "the system should serve to safeguard, enrich, and strengthen the cultural, political, social, and economic fabric of Canada". Canada has a well-developed media sector, but its cultural output—particularly in English films, television shows, and magazines—is often overshadowed by imports from the United States. As a result, the preservation of a distinctly Canadian culture is supported by federal government programs, laws, and institutions such as the Canadian Broadcasting Corporation (CBC), the National Film Board of Canada (NFB), and the Canadian Radio-television and Telecommunications Commission (CRTC). Canadian mass media, both print and digital, and in both official languages, is largely dominated by a "handful of corporations". The largest of these corporations is the country's national public broadcaster, the Canadian Broadcasting Corporation, which also plays a significant role in producing domestic cultural content, operating its own radio and TV networks in both English and French. In addition to the CBC, some provincial governments offer their own public educational TV broadcast services as well, such as TVOntario and Télé-Québec. Non-news media content in Canada, including film and television, is influenced both by local creators as well as by imports from the United States, the United Kingdom, Australia, and France.
Sources: en.wikipedia.org
During FY2018, the federal government spent $4.11 trillion, up $127 billion or 3.2% vs. FY2017 spending of $3.99 trillion. Spending increased for all major categories and was mainly driven by higher spending for Social Security, net interest on the debt, and defense. Spending as % GDP fell from 20.7% GDP to 20.3% GDP, equal to the 50-year average. During FY2017, the federal government spent $3.98 trillion, up $128 billion or 3.3% vs. FY2016 spending of $3.85 trillion. Major categories of FY 2017 spending included: Healthcare such as Medicare and Medicaid ($1,077B or 27% of spending), Social Security ($939B or 24%), non-defense discretionary spending used to run federal Departments and Agencies ($610B or 15%), Defense Department ($590B or 15%), and interest ($263B or 7%). Expenditures are classified as "mandatory", with payments required by specific laws to those meeting eligibility criteria (e.g., Social Security and Medicare), or "discretionary", with payment amounts renewed annually as part of the budget process. Around two thirds of federal spending is for "mandatory" programs. CBO projects that mandatory program spending and interest costs will rise relative to GDP over the 2016–2026 period, while defense and other discretionary spending will decline relative to GDP.
Viral vectors are genetically engineered viruses carrying modified viral DNA or RNA that has been rendered noninfectious, but still contain viral promoters and the transgene, thus allowing for translation of the transgene through a viral promoter. However, because viral vectors frequently lack infectious sequences, they require helper viruses or packaging lines for large-scale transfection. Viral vectors are often designed to permanently incorporate the insert into the host genome, and thus leave distinct genetic markers in the host genome after incorporating the transgene. For example, retroviruses leaves a characteristic retroviral integration pattern after insertion that is detectable and indicates that the viral vector has incorporated into the host genome.
== Treatment == The main goal of treatment is to treat shock and preserve kidney function. Initially, this is done through the administration of generous amounts of intravenous fluids, usually isotonic saline (0.9% weight per volume sodium chloride solution). In victims of crush syndrome, it is recommended to administer intravenous fluids even before they are extracted from collapsed structures. This will ensure sufficient circulating volume to deal with the muscle cell swelling (which typically commences when blood supply is restored), and to prevent the deposition of myoglobin in the kidneys. Amounts of 6 to 12 liters over 24 hours are recommended. The rate of fluid administration may be altered to achieve a high urine output (200–300 mL/h in adults), unless there are other reasons why this might lead to complications, such as a history of heart failure. While many sources recommend additional intravenous agents to reduce damage to the kidney, most of the evidence supporting this practice comes from animal studies, and is inconsistent and conflicting. Mannitol acts by osmosis to enhance urine production and is thought to prevent myoglobin deposition in the kidney, but its efficacy has not been shown in studies, and there is a risk of worsening kidney function.
=== Broader Arab response === In the broader Arab world, the declaration was seen as a betrayal of the British wartime understandings with the Arabs. The Sharif of Mecca and other Arab leaders considered the declaration a violation of a previous commitment made in the McMahon–Hussein correspondence in exchange for launching the Arab Revolt. Following the publication of the declaration in an Egyptian newspaper, Al Muqattam, the British dispatched Commander David George Hogarth to see Hussein in January 1918 bearing the message that the "political and economic freedom" of the Palestinian population was not in question. Hogarth reported that Hussein "would not accept an independent Jewish State in Palestine, nor was I instructed to warn him that such a state was contemplated by Great Britain". Hussein had also learned of the Sykes–Picot Agreement when it was leaked by the new Soviet government in December 1917, but was satisfied by two disingenuous messages from Sir Reginald Wingate, who had replaced McMahon as High Commissioner of Egypt, assuring him that the British commitments to the Arabs were still valid and that the Sykes–Picot Agreement was not a formal treaty.
=== Physiology === Nickel allergy results in a skin response after the skin comes in contact with an item that releases a large amount of nickel from its surface. It is commonly associated with nickel-containing belt buckles coming into prolonged contact with the skin. The skin reaction can occur at the site of contact, or sometimes spread beyond to the rest of the body. Free (released) nickel that is able to penetrate the skin is taken up by scavenger (dendritic) cells and then presented to the immune system T-Cells. With each subsequent exposure to nickel these T cells become stimulated and duplicate themselves. With enough exposure to nickel, the amassing clones of T-cells reach "threshold" and the skin develops a rash. The rash can appear as acute, subacute, or chronic eczema-like skin patches, primarily at the site of contact with the nickel (e.g., earlobe from nickel earrings). From the time of exposure, the rash usually appears within 12–120 hours and can last for 3–4 weeks or for the continued duration of nickel contact/exposure. Three simultaneous conditions must occur to trigger Ni-ACD:
Sources: en.wikipedia.org
Following its reconstitution under the Local Government Act 1972, elections were held for Lancashire County Council on 12 April 1973. All 94 wards were up for election and all wards returned one councillor by FPTP, with the exception of Preston No. 1 and Preston No. 4, which returned two councillors each by plurality block voting. A Conservative majority was returned.
Many public health initiatives are moving towards a more standardized approach at multiple levels: among local facilities (especially long-term and acute care), regional hospitals, national institutions, and global practices. A standardized approach of prevention may help to more effectively reduce the emergence of CRE. An infection control plan was implemented at the Kaplan Medical Center in Israel to control a hospital outbreak of carbapenem-resistant K. pneumoniae. The comprehensive plan included guidelines for cohorting patients in separate locations, cleaning with 1,000 ppm hypochlorite, screening for isolates from rectal swabs, and distribution of educational instruction sheets, lectures for all medical staff, and training. The hospital also implemented an automated computer system that updated patient charts when new cases were reported, if patients were carriers, and what precautions to take when dealing with such patients. This plan was evaluated in a quasiexperimental study through the incidence of clinical cases, the rate of cross-infection, and the rate of screening for carriage in admitted patients with increased risk of carriage. The study had a 16-fold decrease in the incidence of resistant K. pneumoniae, which was sustained for 30 months. The plan can provide a model for other hospitals to contain outbreaks of carbapenem-resistant bacteria. A reduction in the use of unnecessary invasive devices, including urinary catheters, could help reduce CRE transmission.
=== Disorders involving the immune mechanism === 279 Disorders involving the immune mechanism 279.0 Deficiency of humoral immunity 279.00 Hypogammaglobulinemia unspecified 279.01 Selective IgA immunodeficiency 279.02 Selective IgM immunodeficiency 279.03 Other selective immunoglobulin deficiencies 279.04 Congenital hypogammaglobulinemia 279.05 Immunodeficiency with increased IgM 279.06 Common variable immunodeficiency 279.09 Other deficiency of humoral immunity 279.1 Deficiency of cell-mediated immunity 279.10 Immunodeficiency with predominant t-cell defect unspecified 279.11 DiGeorge syndrome 279.12 Wiskott–Aldrich syndrome 279.13 Nezelof syndrome 279.19 Other deficiency of cell-mediated immunity 279.2 Combined immunity deficiency Severe combined immunodeficiency 279.3 Unspecified immunity deficiency 279.4 Autoimmune disease not elsewhere classified 279.5 Graft-versus-host disease 279.8 Other specified disorders involving the immune mechanism 279.9 Unspecified disorder of immune mechanism
=== Lactones === gamma-Decalactone intense peach flavor gamma-Nonalactone coconut odor, popular in suntan lotions delta-Octalactone creamy note Jasmine lactone powerful fatty-fruity peach and apricot Massoia lactone powerful creamy coconut Wine lactone sweet coconut odor Sotolon (maple syrup, curry, fenugreek)
The first clinical study of vosilasarm, a small (n=22) phase 1 study in women with metastatic breast cancer, was started in 2017 and completed in 2020, with results published in 2019, 2020, and 2022. As of March 2023, vosilasarm is in phase 1/2 clinical trials for the treatment of breast cancer. Aside from its development as a potential pharmaceutical drug, vosilasarm is on the World Anti-Doping Agency list of prohibited substances and is sold for physique- and performance-enhancing purposes by black-market Internet suppliers. Vosilasarm is often used in these contexts at doses that have not been evaluated in clinical trials, with unknown effectiveness and safety. Many products sold online that are purported to be a specific SARM either contain none or contain other unrelated substances. Social media has played an important role in facilitating the widespread non-medical use of SARMs.
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.